Weekly dose of exenatide shows benefits
A once-weekly formulation of the drug exanetide in patients with Type 2 diabetes provides better glycaemic control than the current twice-daily regimen, research has found.
In a trial of 259 patients given either a subcutaneous 2mg dose weekly or a SC 10µg daily dose of exenatide, the HbA1c levels of patient given the weekly formation fell by an average of 1.9%, compared with a 1.5% reduction in patients given the twice-daily dose.
Some 77% of patients given the weekly dose reached the target HbA1c of 7.0% or less compared with 61% in the group given standard exenatide treatment.
Dr Daniel Drucker, from the Mount Sinai hospital in Toronto, Canada, concluded: ‘Exenatide once weekly resulted in significantly greater improvements in glycaemic control than exenatide given twice a day, with no increased risk of hypoglycaemia and similar reductions in body weight.'
The study was published in The Lancet this week to coincide with the European Association for the study of Diabetes meeting in Rome.